Drug Status Report

Drug: Amphetamine Analogues

2,5-Dimethoxy-4-iodoamphetamine (I)
2,6-Dichloro-4-dimethylaminoamphetamine (II)

Drug Name Status: I - 2,5-Dimethoxy-4-iodoamphetamine and
II - 2,6-Dichloro-4-dimethylaminoamphetamine are the common names.

Chemical Name: I - 2,5-Dimethoxy-4-iodo-α-methylbenzeneethanamine
II - 2,6-Dichloro-4-dimethylamino-α-methylbenzeneethanamine

Chemical structure:



I



II



Amphetamine

Molecular Formula: I - $C_{11}H_{16}INO_2$; II - $C_{11}H_{18}Cl_2N_2$

Pharmacological class / Application: amphetamine

International status:

US: 2,5-Dimethoxy-4-iodoamphetamine and 2,6-dichloro-4-dimethylaminoamphetamine are not listed on the schedules to the CSA and are not mentioned on the DEA website. Amphetamine is listed in Schedule II to the CSA so the analogue provisions of the CSA should apply. As 2,5-dimethoxy-4-iodoamphetamine and 2,6-dichloro-4-dimethylaminoamphetamine are analogues of amphetamine, they should be controlled by the CSA. The DEA would have to confirm the status of the two substances.

United Nations: The substances are not listed on the Yellow List - List of Narcotic Drugs under International Control nor the Green List - List of Psychotropic Substances under International Control.

Canadian Status: The drug is currently not listed specifically on the CDSA. However, Item 1 of Schedule III is, “Amphetamines, their salts, derivatives, isomers and analogues and salts of derivatives, isomers and analogues including.” As analogue is defined in the CDSA as, “a

substance that, in relation to a controlled substance, has a substantially similar chemical structure", 2,5-dimethoxy-4-iodoamphetamine and 2,6-dichloro-4-dimethylaminoamphetamine must be considered analogues of amphetamine (structure above).

Recommendation: 2,5-Dimethoxy-4-iodoamphetamine and 2,6-dichloro-4-dimethylaminoamphetamine are included item 1 of Schedule III to the CDSA and are controlled substances. Their salts are also included in item 1 of Schedule III.

February 23, 2008